HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Prisant, L. M. Search for Related Content PubMed PubMed Citation Articles by Prisant, L. M. Social Bookmarking                   What's this?

Preventing Type II Diabetes Mellitus

From the Medical College of Georgia, Augusta.

Burgeoning obesity is increasing the prevalence of type II diabetes mellitus. As a consequence, there will be an even greater burden of cardiovascular disease, end-stage renal disease, blindness, and lower extremity amputations. If diagnosed, impaired glucose tolerance presents an opportunity for intervention that potentially could delay or prevent the development of diabetes. Recent prospective studies document the effectiveness of exercise and weight reduction in preventing diabetes. Metformin is less effective than intense lifestyle interventions. Acarbose, losartan, orlistat, pravastatin, ramipril, and hormone replacement therapy are associated with lower rates of the development of diabetes. The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial and the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial were designed to assess not only the prevention of diabetes but also the impact on cardiovascular morbidity and mortality.

Key Words: Diabetes mellitus • glucose intolerance • prevention • controlled trials • lifestyle • review

Address for reprints: L. Michael Prisant, MD, 1120 Fifteenth Street, BI-5082, Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, GA 30912.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. L Gillies, K. R Abrams, P. C Lambert, N. J Cooper, A. J Sutton, R. T Hsu, and K. Khunti Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis BMJ, February 10, 2007; 334(7588): 299 - 299. [Abstract] [Full Text] [PDF]

				R. A Ajjan and P. J Grant Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 147 - 158. [Abstract] [PDF]

				M. J. Krantz and P. S. Mehler Angiotensin-Converting Enzyme Inhibitors and Diuretics: Optimal Combination Therapy Ann Intern Med, December 7, 2004; 141(11): 893 - 893. [Full Text] [PDF]

				A. Segal and B. F. Palmer Hyperkalemia and Inhibitors of the Renin-Angiotensin-Aldosterone System N. Engl. J. Med., December 2, 2004; 351(23): 2450 - 2451. [Full Text] [PDF]

				L. M. Prisant Diabetes Mellitus: An Imperative for Prevention and Intense Management J. Clin. Pharmacol., April 1, 2004; 44(4): 394 - 396. [Full Text] [PDF]